Article
Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib.
Clinical lung cancer - 1 May 2022
White Maya N, Piper-Vallillo Andrew J, Gardner Rebecca M, Cunanan Kristen, Neal Joel W, Das Millie, Padda Sukhmani K, Ramchandran Kavitha, Chen Thomas T, Sequist Lecia V, Piotrowska Zofia, Wakelee Heather A
Abstract excerpt
INTRODUCTION: Patients with EGFR-mutant lung cancer who have had disease progression on osimertinib commonly receive platinum doublet chemotherapy, but whether adding immunotherapy or bevacizumab provides additional benefit is unknown. MATERIALS AND METHODS: This was a retrospective analysis at 2 university-affiliated institutions. Patients with EGFR-mutant lung cancer who had progression on osimertinib and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.